| scholarly article | Q13442814 |
| P2093 | author name string | M Guillaume Wientjes | |
| Jessie L-S Au | |||
| Ho Lun Wong | |||
| Ze Lu | |||
| Zancong Shen | |||
| P2860 | cites work | A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma | Q24322614 |
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| Targeting survivin in cancer therapy: fulfilled promises and open questions | Q28291799 | ||
| Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Q29615957 | ||
| Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. | Q30320605 | ||
| Small-volume extrusion apparatus for preparation of large, unilamellar vesicles | Q30965369 | ||
| Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes | Q31042568 | ||
| Drug delivery and transport to solid tumors | Q35563687 | ||
| Revealing the world of RNA interference | Q35889563 | ||
| Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors | Q36677197 | ||
| Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. | Q36792039 | ||
| Systemic siRNA delivery via hydrodynamic intravascular injection | Q36795055 | ||
| Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer | Q37003211 | ||
| Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. | Q37221348 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| Chlamydia pneumoniae affect surfactant trafficking and secretion due to changes of type II cell cytoskeleton | Q37869704 | ||
| Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells | Q40225961 | ||
| Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. | Q40359097 | ||
| Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells | Q40495806 | ||
| Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest | Q40599574 | ||
| Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma | Q44948301 | ||
| RNA interference against Hec1 inhibits tumor growth in vivo | Q45886214 | ||
| Targeting oncogenes with siRNAs. | Q51757691 | ||
| Tumor priming enhances delivery and efficacy of nanomedicines. | Q53560453 | ||
| A simplified method for production and growth of multicellular tumor spheroids | Q67684815 | ||
| Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule | Q73447413 | ||
| Determinants of paclitaxel penetration and accumulation in human solid tumor | Q78016374 | ||
| Regional heterogeneity and pharmacodynamics in human solid tumor histoculture | Q78126622 | ||
| Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy | Q81073226 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| P304 | page(s) | 833-840 | |
| P577 | publication date | 2011-03-29 | |
| P1433 | published in | Molecular Pharmaceutics | Q3011140 |
| P1476 | title | Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures | |
| P478 | volume | 8 |
| Q38749605 | A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy |
| Q26828808 | Advances in the formation, use and understanding of multi-cellular spheroids |
| Q36312156 | Cancer cell spheroids as a model to evaluate chemotherapy protocols |
| Q36791673 | Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities |
| Q53381586 | Evaluation of interstitial protein delivery in multicellular layers model. |
| Q57371952 | Hoechst 33258–conjugated hyaluronated fullerene for efficient photodynamic tumor therapy and necrotic tumor targeting |
| Q39033531 | Hyperthermia-induced drug delivery from thermosensitive liposomes encapsulated in an injectable hydrogel for local chemotherapy |
| Q41807205 | Hypoxia-targeted siRNA delivery |
| Q36848111 | Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming |
| Q92644673 | Nanocarrier-based drug combination therapy for glioblastoma |
| Q38854876 | Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. |
| Q36092777 | Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors |
| Q37340860 | Photoswitchable nanoparticles for in vivo cancer chemotherapy |
| Q38071901 | The holistic 3M modality of drug delivery nanosystems for cancer therapy |
| Q37714442 | Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors |
| Q57374236 | pH-sensitive siRNA delivery systems |
Search more.